Intranasal delivery of neutralizing antibodies for prophylatic COVID-19 treatments

被动免疫技术有可能减少SARS-CoV-2在我们的社区和长期疗养院等高危环境中的传播。在接触SARS-CoV-2之前或之后不久，鼻腔注射病毒中和抗体可以防止感染，这是被动免疫的一种形式。因此，鼻腔注射中和抗体可以防止暴露者患病，防止疾病传播。被动免疫疗法需要作为疫苗的替代品，而疫苗的开发和全面实施可能需要数年时间。此外，老年人等高危人群的疫苗应答率很低，限制了疫苗的有效性。 为此，我们正在开发输送技术，以维持SARS-CoV-2中和抗体的输送，这种抗体可以通过简单的鼻腔喷雾给予。我们的目标是减少病毒在社区中的传播，这将允许更高质量的生活，并有可能消除封锁的需要。

Technologies for passive immunity have the potential to decrease the transmission of SARS-CoV-2 in our communities and high-risk environments such as long term care homes. The intranasal delivery of virus neutralizing antibodies prior or soon after exposure to SARS-CoV-2 can prevent infection, which is a form of passive immunity. Therefore, intranasal delivery of neutralizing antibodies can prevent exposed individuals from getting sick and prevent the spread of disease. Passive immunity therapies are required as an alternative to vaccines, which may take multiple years to develop and fully implement. Furthermore, high risk populations such as the elderly have poor vaccine response rates, limiting their effectiveness. To this end, we are developing delivery technologies to sustain the delivery of neutralizing antibodies for SARS-CoV-2 that can be administered through a simple nasal spray. Our goal is to decrease virus transmission in the community, which will allow for a greater quality of life and potentially eliminate the need for lockdowns.